rs41298997 — IKBKE

Intronic variant in IKBKE (IKK-epsilon) associated with psoriasis susceptibility; the T allele modestly increases risk by influencing the dual NF-kB/type I interferon signaling node encoded by this kinase

See your personal result for IKBKE

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IKBKE — The Dual-Pathway Kinase at the Heart of Psoriasis Susceptibility

Psoriasis is not a single disease driven by a single pathway — it is the collision of two inflammatory cascades: the NF-kB signaling axis11 NF-kB signaling axis
NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a master transcription factor that controls genes for TNF-α, IL-1β, IL-6, and many other pro-inflammatory cytokines; it is the primary driver of the keratinocyte hyperproliferation and immune cell recruitment seen in psoriatic plaques and the type I interferon axis22 type I interferon axis
Type I interferons (IFN-α and IFN-β) are signaling proteins produced by plasmacytoid dendritic cells and keratinocytes that amplify innate immune responses; they are particularly prominent in early psoriasis lesions and plaque initiation. The gene IKBKE encodes IKK-epsilon (IKKε)33 IKK-epsilon (IKKε)
Inhibitor of NF-kB kinase subunit epsilon — a serine/threonine kinase related to canonical IKKα and IKKβ but with distinct substrates and a unique position at the crossroads of innate antiviral and inflammatory signaling, a kinase that sits at the intersection of both pathways and governs the amplitude of both responses simultaneously. The rs41298997 intronic variant in IKBKE was identified in the largest psoriasis GWAS to date as a novel, genome-wide-significant susceptibility locus, with the T allele conferring a modest but statistically robust increase in psoriasis risk.

The Mechanism

IKKε operates at a hub where three signaling pathways converge. First, it phosphorylates IRF3 and IRF744 IRF3 and IRF7
Interferon regulatory factors 3 and 7 — transcription factors that, once phosphorylated by IKKε or its homolog TBK1, undergo conformational change, dimerize, and translocate to the nucleus to activate IFN-β and IFN-α gene transcription; this is the primary amplifier of the antiviral and early innate immune response, driving type I interferon production. Second, IKKε phosphorylates inhibitors of NF-kB (IkBs), freeing the NF-kB complex to translocate to the nucleus and switch on pro-inflammatory cytokine genes including TNF-α, IL-1β, and IL-6. Third, IKKε phosphorylates STAT1 at serine-70855 STAT1 at serine-708
This phosphorylation selectively promotes assembly of the ISGF3 complex (STAT1:STAT2:IRF9) over GAF (STAT1 homodimer) formation; ISGF3 drives interferon-stimulated gene expression while GAF drives a different transcriptional program; IKKε thus acts as a molecular switch that shapes which arm of the interferon response dominates, tuning the balance between type I and type II interferon-driven transcriptional programs.

The rs41298997 variant lies within an intron of IKBKE and is presumed to influence gene expression or splicing rather than protein structure, although the exact regulatory mechanism has not been characterized at the molecular level. Its location at 1q32.1 — a chromosomal region enriched for immune regulatory elements — and the genome-wide significance of its association with psoriasis places it in the same functional class as other regulatory psoriasis loci that modulate pathway-level signaling intensity rather than abolishing it.

The Evidence

The primary evidence comes from the Tsoi et al. 2017 meta-analysis66 Tsoi et al. 2017 meta-analysis
Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nature Communications, 2017. Combined effective sample size >39,000 individuals across eight Caucasian cohorts., which identified 16 novel genome-wide-significant psoriasis loci. The rs41298997-T allele reached genome-wide significance (OR=1.13, p=2.37×10⁻⁸) with a risk allele frequency of approximately 19% in cases versus 18% in controls — a small but consistent enrichment across tens of thousands of individuals. The study performed pathway analysis showing that genes at novel loci, including IKBKE, clustered in the "Regulation of I-kB kinase/NF-kB cascade" pathway (11 associated loci) and in T-cell regulatory elements, confirming the biological relevance of the association.

The molecular role of IKKε was established by two mechanistic studies. Fitzgerald et al. 200377 Fitzgerald et al. 2003
Fitzgerald KA et al., IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunology 2003. demonstrated that IKKε and TBK1 together are required for IRF3-mediated IFN-β induction in response to viral signals, placing IKKε as an essential gatekeeper of innate antiviral immunity. Ng et al. 201188 Ng et al. 2011
Ng SL et al., IκB kinase ε (IKKε) regulates the balance between type I and type II interferon responses. PNAS 2011. then showed that IKKε does not merely activate interferons but actively shapes which interferon-driven transcriptome is expressed by determining whether ISGF3 or GAF forms — a distinction with profound implications for whether cells respond in an antiviral versus inflammatory mode.

The OR of 1.13 per T allele is modest by Mendelian disease standards but is consistent with the polygenic architecture of psoriasis, where dozens of loci each contribute small effects that combine to produce the 60–80% heritability of the disease. The T allele frequency is notably higher in East Asian populations (~61%) compared to Europeans (~24%) and Africans (~18%), which may contribute to differences in psoriasis prevalence and phenotype across ancestries.

Practical Implications

For CT heterozygotes and TT homozygotes, the most actionable implication is awareness: psoriasis tends to develop in genetically predisposed individuals following environmental triggers — streptococcal throat infections, mechanical skin trauma (Koebner phenomenon), certain medications (lithium, beta-blockers, antimalarials, rapid steroid withdrawal), and psychological stress. Recognizing early plaque formation and seeking dermatological evaluation promptly improves outcomes significantly.

The IKBKE locus is of particular interest for therapy: IKKε inhibition has been investigated as a therapeutic strategy in inflammatory disease, and IKKε's dual role in NF-kB and interferon signaling means that dysregulation at this node may influence both the initiating events (interferon-driven plasmacytoid dendritic cell activation) and the sustaining events (NF-kB-driven keratinocyte hyperproliferation and cytokine amplification) in psoriasis pathogenesis. While no IKKε-targeted therapy is currently approved for psoriasis, existing biologics that block downstream cytokines (anti-IL-17, anti-IL-23, anti-TNF) all target effectors downstream of the NF-kB pathway that IKBKE feeds into.

Interactions

IKBKE functionally interacts with STAT4 (rs7574865) in psoriasis susceptibility: STAT4 is activated by IL-12 and IL-23 downstream of the NF-kB pathway that IKKε activates. Individuals carrying risk alleles at both loci may have amplified Th1/Th17 polarization, as IKKε drives the upstream cytokine milieu (via IFN and NF-kB signaling) while STAT4 determines how sensitively T cells respond to those cytokines. This interaction has not been formally tested in psoriasis but parallels the well-documented IRF5–STAT4 interaction in lupus susceptibility.

The IKBKE-encoded kinase also functions within a complex containing TBK1 and scaffold proteins including TANK, NAP1, and SINTBAD. Variants affecting other members of this kinase complex (TBK1 variants) may compound with rs41298997 to amplify innate immune signaling, though no interaction data specific to psoriasis yet exist.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Standard IKBKE function; typical NF-kB and interferon signaling balance

You carry two copies of the C (reference) allele at rs41298997. This is the common genotype in European and African populations (~57% globally carry this genotype). At this locus, you do not carry the T allele that was associated with a modest increase in psoriasis risk in a large-scale GWAS meta-analysis of over 39,000 individuals. This genotype is associated with typical IKBKE gene activity and the baseline balance of NF-kB and interferon signaling that IKKε regulates.

CT Intermediate

One copy of the psoriasis-associated T allele at the IKBKE locus

IKBKE encodes IKK-epsilon (IKKε), a noncanonical IkB kinase that activates both NF-kB (by phosphorylating IkB inhibitors) and the type I interferon pathway (by phosphorylating IRF3, IRF7, and STAT1). This dual role places IKKε at the intersection of the two pathways most enriched in psoriasis GWAS signals. The rs41298997 variant is intronic and most likely affects gene expression or alternative splicing in immune cells rather than altering the kinase's protein structure.

The OR of 1.13 per T allele means that each copy of T confers approximately 13% increased odds of developing psoriasis compared to carrying the C allele. As a CT heterozygote, your overall genetic risk from this locus is modest. Psoriasis is highly polygenic, and the presence or absence of triggers (streptococcal infection, skin trauma, certain medications) may be as important as the genetic background in determining whether disease develops.

TT High Risk

Two copies of the psoriasis-associated T allele — highest genetic load at this IKBKE locus

Psoriasis genetics is additive across dozens of loci, and rs41298997 is one of approximately 63 confirmed susceptibility loci for European-ancestry individuals. The IKBKE locus contributes to the "Regulation of I-kB kinase/ NF-kB cascade" pathway, which clusters with 10 other psoriasis loci — making NF-kB dysregulation one of the strongest pathway-level signals in psoriasis genetics.

Mechanistically, IKKε phosphorylates IRF3 and IRF7 to trigger IFN-β production, and phosphorylates IkBα to release NF-kB for nuclear translocation. It also phosphorylates STAT1 at serine-708, which shifts the interferon response from a STAT1-homodimer (GAF/type II interferon) program toward a STAT1:STAT2:IRF9 (ISGF3/type I interferon) program. Elevated or dysregulated IKKε activity thus amplifies both the acute inflammatory response (NF-kB arm) and the innate antiviral/plasmacytoid dendritic cell activation (IFN-I arm) that together initiate psoriatic lesions.

TT homozygotes benefit from proactive monitoring and early intervention if symptoms develop, as treatments initiated in early disease — before joint damage (psoriatic arthritis) — show substantially better long-term outcomes. Topical treatments suffice for mild disease; moderate-to-severe psoriasis responds well to biologics targeting IL-17, IL-23, or TNF-α, all of which act downstream of the NF-kB pathway that IKKε feeds into.